Animal Health Generics 2017: Intellectual Property and Patents, Regulation Issues, Strategies for R&D and Generics Companies, Company Profiles, Industry Associates

/EIN News/ -- Dublin, Aug. 11, 2017 (GLOBE NEWSWIRE) -- The "Animal Health Generics 2017: Intellectual Property and Patents, Regulation Issues, Strategies for R&D and Generics Companies, Company Profiles, Industry Associates " report has been added to Research and Markets' offering.

In 2015, the global animal health market was worth an estimated $30bn

This new thoroughly revised and updated Generics report focuses primarily on the European and North American markets that comprise around 67% of the global market for animal health products. Also fully reviewed are the EU and North American veterinary generics markets, with a specific focus on veterinary pharmaceuticals (such as anti-infectives and parasiticides), as well as medicinal feed additives where appropriate.

The global animal health market is dominated by pharmaceuticals (57% of sales), biologicals (29%) and medicinal feed additives (14%).

While medicated feed is cheap, using primarily established active ingredients (AIs) and often antimicrobials produced in bulk as a commodity product, increasing regulation is making this sector less attractive.

Products based on patented AIs are probably worth just 5% of the market, which reflects a lack of innovation, that many AIs are out of patent, and that pioneer companies frequently retain the controlling share.

Because of the huge costs involved, generic biologicals (or biosimilars) will only be open to large players. The high molecular complexity, multifaceted production methods and stability issues, coupled with smaller returns than for human pharmaceuticals, may prove insurmountable for smaller companies.

Key Topics Covered:


1. Overview
1.1 Focus of the report
1.2 Definition of generics
1.2.1 EU definition
1.2.2 US definition
1.3 Naming conventions
1.3.1 Identifiers
1.3.2 INN
1.4 Counterfeit medicines
1.5 Evolution of human and animal medicine market
1.6 Cost of developing new products
1.7 Emergence of generics
1.8 Innovation impeded
1.9 References

2. Intellectual Property
2.1 Summary
2.2 Introduction
2.3 WIPO
2.4 Patents
2.4.1 Types of patent
2.4.2 Company example
2.4.3 Points of note
2.5 Filing a patent
2.6 PCT
2.7 WTO and TRIPS
2.8 Patent situation in the EU
2.8.1 Overview
2.8.2 Establishment of an EU unitary patent
2.9 Patent situation in the US
2.10 Patent situation in India
2.10.1 Overview
2.10.2 Compulsory licenses
2.11 Patent situation in China
2.12 Extended patent protection
2.12.1 EU - Supplementary Protection Certificates
2.12.2 US - Hatch-Waxman legislation
2.13 Experimental use exceptions (Bolar exemptions)
2.13.1 EU
2.13.2 US
2.14 Registration data exclusivity
2.15 Trademarks
2.15.1 Background
2.15.2 Think Outside the Box
2.15.3 Plan Ahead
2.15.4 Select Alternate Names
2.15.5 Trademark Clearance
2.15.6 Invest in Targeted Protection
2.16 References

3. Registration issues
3.1 Summary
3.2 Abridged registration for generics
3.3 US
3.3.1 Veterinary pharmaceuticals approved under the FDA
3.3.1.1 Market exclusivity
3.3.1.2 Registration requirements
3.3.1.3 Suitability Petition
3.3.1.4 Fees
3.3.1.5 Bioequivalence
3.3.2 Ectoparasiticides approved under the EPA
3.3.3 Veterinary biologics approved under the USDA
3.4 EU
3.4.1 Legal background
3.4.2 Abridged applications for generics
3.4.2.1 Directive 2001/82/EC
3.4.2.2 Directive 2004/28/EC
3.4.3 Registration procedures
3.4.4 Proposal for a veterinary medicinal products regulation (revising Directive 2001/82/EC and Directive 2004/28/EC)
3.4.4.1 Overview of Commission proposal
3.4.4.2 Increased data protection proposals
3.4.4.3 EU-wide database
3.4.4.4 ComAgri amendments
3.4.4.5 ComEnvi amendments
3.4.4.6 Proposal for a medicated feed regulation (revising Directive 90/167/EEC)
3.4.4.7 Proposal for a Regulation amending Regulation 726/2004
3.5 References

4. Significance of generics market
4.1 Summary
4.2 Global animal health market
4.3 Global animal health market for generic veterinary pharmaceuticals
4.4 Generics in the pharmaceuticals market
4.4.1 Human pharmaceuticals market
4.4.2 Veterinary pharmaceuticals market
4.4.3 Reasons for differences between the two markets
4.5 Generics in the biologicals market
4.6 Generics in the medicated feed additives market
4.7 Distribution
4.8 Factors favoring generic production
4.9 Regional markets
4.9.1 EU
4.9.2 US
4.9.2.1 Background
4.9.2.2 US FDA approvals
4.9.2.3 Companion animal market
4.9.3 Brazil
4.9.4 China
4.10 Future trends
4.11 References

5. Strategies for R&D companies
5.1 Summary
5.2 Introduction
5.3 Protecting existing IPR
5.3.1 Patents
5.3.2 Trademarks
5.3.3 Data protection
5.4 Developing related patents
5.4.1 Improved manufacturing processes
5.4.2 Improved formulations and delivery methods
5.4.2.1 Background
5.4.2.2 Types of innovative delivery
5.4.2.3 Slow-release bolus delivery
5.4.2.4 Implants
5.4.2.5 Extended/controlled release injections
5.4.2.6 Higher dosing
5.4.2.7 Rapidly disintegrating tablets
5.4.2.8 Lingual spray
5.4.2.9 Pour-on and spot-on delivery products
5.4.2.10 Dermal treatments for companion animals
5.4.3 Combining AIs
5.5 Acquisition
5.6 Marketing strategies
5.6.1 Lifecycle management
5.6.2 Promoting the brand name
5.6.3 Competing on quality
5.6.4 Competing on price
5.7 Distribution issues
5.8 Manufacturing issues
5.9 Parallel trade and its effects on generics
5.10 Focus of R&D companies
5.11 References

6. Strategies for generics companies
6.1 Summary
6.2 Changing image of generics
6.3 Pricing
6.4 Types of generics companies
6.4.1 R&D companies
6.4.1.1 Ivermectin
6.4.1.2 Fipronil
6.4.2 Manufacturers of generic bulk materials
6.4.3 Generic product traders
6.4.4 Generics formulators
6.4.5 Contract manufacturing
6.4.6 Wholesalers and distributors
6.4.7 Generic human pharmaceutical specialists
6.5 Branded generics
6.6 References

7. Company profiles
7.1 Bayer Animal Health
7.1.1 Background
7.1.2 Products
7.1.2.1 Overview
7.1.3 Strategy
7.1.3.1 Imidacloprid
7.1.3.2 Baytril (enrofloxacin)
7.1.3.3 Acquisition of Teva's animal health business
7.2 Bimeda
7.2.1 Background
7.2.2 Products
7.2.3 Strategy
7.2.3.1 Global focus
7.2.3.2 Acquisitions
7.2.3.3 Manufacturing
7.3 Boehringer Ingelheim
7.3.1 Background
7.3.2 Products
7.3.3 Strategy
7.3.3.1 R&D investment
7.3.3.2 Vaccines
7.3.3.3 Pharmaceuticals
7.3.3.4 Product lifecycle management
7.3.3.5 Future direction
7.4 Ceva Sant Animale
7.4.1 Background
7.4.2 Products
7.4.2.1 Background
7.4.3 Strategy
7.4.3.1 Formulations
7.4.3.2 Packaging
7.4.3.3 Applicators
7.4.3.4 Distribution
7.4.3.5 Recent patents
7.4.3.6 US
7.5 Dechra Pharmaceuticals
7.5.1 Background
7.5.1.1 EU Pharmaceuticals
7.5.1.2 North America Pharmaceuticals
7.5.2 Products
7.5.2.1 Overview
7.5.2.2 Putney products
7.5.3 Strategy
7.5.3.1 Expansion plans
7.5.3.2 Company acquisitions
7.5.3.3 Antibiotics
7.6 Elanco
7.6.1 Background
7.6.2 Products
7.6.2.1 Overview
7.6.3 Strategy
7.6.3.1 Research
7.6.3.2 Tylan (tylosin)
7.6.3.3 Acquisitions
7.7 Huvepharma
7.7.1 Background
7.7.2 Products
7.7.2.1 Overview
7.7.3 Strategy
7.7.3.1 Manufacturing
7.7.3.2 Acquisitions
7.7.3.3 US market
7.8 Merck
7.8.1 Background
7.8.2 Products
7.8.2.1 Overview
7.8.3 Strategy
7.8.3.1 R&D focus
7.8.3.2 Acquisition focus
7.8.3.3 Patents
7.8.3.4 Zilmax (zilpaterol hydrochloride)
7.8.3.5 Engagement with veterinarians, livestock producers and consumers
7.8.3.6 Generics competition
7.9 Norbrook
7.9.1 Background
7.9.2 Products
7.9.2.1 Overview
7.9.3 Strategy
7.9.3.1 Innovation
7.9.3.2 Enroflox 100 (enrofloxacin)
7.9.3.3 Partnerships
7.9.3.4 Capital investment
7.10 Perrigo
7.10.1 Background
7.10.2 Products
7.10.3 Strategy
7.10.3.1 Product development
7.10.3.2 Product promotion
7.10.3.3 Fipronil and methoprene
7.11 Vetoquinol
7.11.1 Background
7.11.2 Products
7.11.2.1 Overview
7.11.3 Strategy
7.11.3.1 Sales and marketing initiatives geared to reference products
7.11.3.2 Product launches
7.11.3.3 Lifecycle management
7.11.3.4 Acquisitions
7.11.3.5 Agreements with other companies
7.12 Zoetis
7.12.1 Background
7.12.2 Products
7.12.2.1 Overview
7.12.2.2 Antibiotics
7.12.2.3 Competition from generics products
7.12.2.4 Rimadyl (carprofen)
7.12.3 Strategy
7.12.3.1 Intellectual property
7.12.3.2 Product lifecycle management
7.12.3.3 Moving away from low-margin, older products
7.12.3.4 Sales and marketing
7.12.3.5 Moving into new areas
7.12.3.6 Developing selected generics
7.13 References
7.13.1 Bayer
7.13.2 Bimeda
7.13.3 Boehringer Ingelheim
7.13.4 Ceva
7.13.5 Dechra Pharmaceuticals
7.13.6 Elanco
7.13.7 Huvepharma
7.13.8 Merck Animal Health
7.13.9 Norbrook
7.13.10 Perrigo
7.13.11 Vetoquinol
7.13.12 Zoetis

8. Industry associations
8.1 EGGVP
8.2 GADA (US)

For more information about this report visit https://www.researchandmarkets.com/research/3dj7h5/animal_health

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Related Topics: Generic Drugs , Animal Healthcare/Veterinary
                    

Primary Logo

Powered by EIN News